Vaccine candidates for hantavirus remain in early preclinical or Phase I/II stages as of September 2026, with no candidates advancing to pivotal efficacy trials or regulatory review that could enable approval this year. Promising mRNA platforms, including single-dose formulations showing full protection in hamster models against Andes virus and collaborative work by Moderna and Korea University, have demonstrated immunogenicity in rodents but face standard multi-year timelines for human testing, manufacturing scale-up, and safety data required by agencies like the FDA. Recent attention from the resolved MV Hondius outbreak has not accelerated late-stage progress, consistent with the market-implied 95.5% probability of no vaccine in 2026. A major funding surge or emergency authorization could theoretically shift timelines, though current conditions make that improbable.